TUSTIN, Calif., Aug. 29, 2019 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.

-- Achieved Strong Second Quarter Revenue of $18.3 Million and Gross Margin of 18% -- -- Fiscal 2020 Projected Revenue of $64 to $67 Million Reaffirmed -- -- Launched Expanded.

Avid Bioservices (CDMO) delivered earnings and revenue surprises of -100.00% and -19.14%, respectively, for the quarter ended January 2020. Do the numbers hold clues to what lies ahead for the stock?

Avid Bioservices (NASDAQ:CDMO) reported Q3 results.Quarterly Results • Earnings per share decreased 20% year over year to a loss of $0.06, which missed the estimate by $0.02.• Revenue of $13,585,000 less by 1.42% year over year, which missed the estimate of $15,420,000.Outlook • Q4 revenue expected to be between $55,000,000 and $59,000,000.How To Listen To The Conference Call • Date: Mar 10, 2020• Time: 06:04 AM ETView more earnings on CDMO• Webcast URL: https://edge.media-server.com/mmc/p/vvmbx7zeTechnicals • 52-week high: $8.38• 52-week low: $3.37• Price action over last quarter: Up 12.17%Company Profile Avid Bioservices is a clinical-stage biopharmaceutical company focused on development and current Good Manufacturing Practices (cGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.See more from Benzinga * 146 Biotechnology Stocks Moving In Thursday's Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

TUSTIN, Calif. and MORGAN HILL, Calif., May 06, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing.

Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company has been named a recipient of five 2020 Contract Manufacturing Organization (CMO) Leadership Awards. Presented by the industry publication Life Science Leader and based on market research and surveys conducted by Industry Standard Research (ISR), these awards are intended to honor those companies in the contract manufacturing space that provide their customers with the industry’s highest level of service.

TUSTIN, Calif., March 03, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.

TUSTIN, Calif., March 04, 2020 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.

TUSTIN, Calif., Dec. 02, 2019 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.

-- Achieved First Quarter Revenue of $15.3 Million; Reaffirms Fiscal 2020 Projected Revenue of $64 to $67 Million -- -- Signed Two Contract Manufacturing Agreements with New.

TUSTIN, Calif., July 26, 2019 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Timothy Compton as chief commercial officer. Mr. Compton is an accomplished professional who possesses extensive experience in commercial operations, including sales team management, business development, marketing and corporate development.

Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that its Board of Directors has voted to accelerate the expiration of the Company's Stockholder Rights Plan (often referred to as a “poison pill”). Joseph Carleone, Ph.D., Avid’s Chairman of the Board said, “Since its reconstitution in November 2017, the Board has been continuously seeking to enhance our corporate governance practices and improve long-term stockholder value.

Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Richard (Rich) Richieri as chief operations officer. In this role, Mr. Richieri will oversee Process Development, Clinical and Commercial Manufacturing, Technical Support and Facilities.

Avid Bioservices, Inc. (CDMO) (CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of two senior directors of business development with responsibility for driving CDMO business growth within North America, Europe and Asia. Jason C. Brady, Ph.D. will serve as senior director of business development for the eastern region of North America, as well as Europe.

Companies In The News Are: TLSA, VIR, HEAR, CDMO

-- Recorded Third Quarter Revenue of $13.6 Million -- -- Signed New Customer and Project Expansion Orders with Current Customers for $20 Million  -- -- Adjusting Fiscal 2020.

CDMO earnings call for the period ending July 31, 2019.

TUSTIN, Calif., Oct. 08, 2019 -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working.